CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2

Pharmacologically difficult targets, such as MYC transcription factors, represent a major challenge in cancer therapy. For the childhood cancer neuroblastoma, amplification of the oncogene MYCN is associated with high-risk disease and poor prognosis. Here, we deployed genome-scale CRISPR-Cas9 screen...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Invest
Glavni autori: Chen, Liying, Alexe, Gabriela, Dharia, Neekesh V., Ross, Linda, Iniguez, Amanda Balboni, Conway, Amy Saur, Wang, Emily Jue, Veschi, Veronica, Lam, Norris, Qi, Jun, Gustafson, W. Clay, Nasholm, Nicole, Vazquez, Francisca, Weir, Barbara A., Cowley, Glenn S., Ali, Levi D., Pantel, Sasha, Jiang, Guozhi, Harrington, William F., Lee, Yenarae, Goodale, Amy, Lubonja, Rakela, Krill-Burger, John M., Meyers, Robin M., Tsherniak, Aviad, Root, David E., Bradner, James E., Golub, Todd R., Roberts, Charles W.M., Hahn, William C., Weiss, William A., Thiele, Carol J., Stegmaier, Kimberly
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2017
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5749506/
https://ncbi.nlm.nih.gov/pubmed/29202477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI90793
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items